News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Mark A. Socinski, MD, Advent Health Cancer Institute

Articles by Mark A. Socinski, MD, Advent Health Cancer Institute

NRG1 Fusions in Solid Tumors: The CRESTONE Trial

ByMark A. Socinski, MD, Advent Health Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center

May 12th 2021

Dr Mark Socinski describes the design and findings of the CRESTONE trial.

Tumor Agnostic RET Inhibition: The LIBRETTO-001 Trial

ByMark A. Socinski, MD, Advent Health Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center

May 5th 2021

Lori Wirth, MD, reviews the phase 1/2 LIBRETTO-001 trial.

Latest Updated Articles

Trending on OncLive

FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer

Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM

FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC

NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer

Real-World SEER Data Highlight Age-Related Survival Gap in ICI-Treated Advanced RCC